Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Nuvation Bio (NYSE: NUVB) announced that Founder, President and CEO David Hung and CFO Philippe Sauvage will join a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:55 a.m. ET in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvation Bio (NYSE: NUVB) announced that Founder, President and CEO David Hung and CFO Philippe Sauvage will join a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:55 a.m. ET in New York.
A live webcast and 90-day archive will be available on the company’s investor relations website.
Details
News Market Reaction – NUVB
On May 28, the first trading day after this news, NUVB closed 0.21% above the previous close.
Data tracked by StockTitan Argus for the May 28 session.
Key Figures
- Conference date
- June 3, 2026
- Jefferies Global Healthcare Conference fireside chat
- Start time
- 9:55 a.m. ET
- Scheduled time for Nuvation Bio fireside chat
- Archive duration
- 90 days
- Length of time webcast recording will be available
Historical Context
-
Thermo Fisher collaboration for U.S.-based IBTROZI manufacturing and tech transfer.
-
FDA acceptance of supplemental NDA for IBTROZI with updated duration of response.
-
Announcement of participation in multiple investor conferences with webcasts available.
-
Q1 2026 financial results with IBTROZI revenue, strong cash balance, and clinical updates.
-
NCCN adds taletrectinib (IBTROZI) to CNS cancer guidelines for ROS1+ NSCLC with brain mets.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following the event.
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI ®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-present-at-the-jefferies-global-healthcare-conference-302783463.html
SOURCE Nuvation Bio Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.